Portrait of Mark Terrelonge
ucsf logo

Mark Terrelonge, MD, MPH

He | Him | HisNeurology • Neurology (Neuromuscular Medicine)
ALS & Neurodegenerative Disease Parnassus
415-353-2122
Portrait of Mark Terrelonge
Portrait of Mark Terrelonge
ucsf logo

Mark Terrelonge, MD, MPH

He | Him | HisNeurology • Neurology (Neuromuscular Medicine)
ALS & Neurodegenerative Disease Parnassus
415-353-2122

On this page

About me

Dr. Mark Terrelonge Jr. is a neurologist who cares for patients with nerve and muscle disorders, including amyotrophic lateral sclerosis (ALS); inflammatory nerve diseases, such as Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy; genetic muscle and nerve disorders; and disorders of the neuromuscular junction, such as myasthenia gravis.

At the UCSF School of Medicine, Terrelonge serves as an assistant director for the residency program in neurology and as a lecturer on weakness related to neuromuscular disorders. Other endeavors include developing satellite clinics for people with ALS or other neuromuscular conditions who live in rural areas of Northern California and Hawaii. He is also designing a blueprint for establishing multidisciplinary ALS clinics in the United States and abroad using telehealth to make subspeciality neurological services available to more people. At Zuckerberg San Francisco General Hospital and Trauma Center, he is launching a specialty clinic to provide underserved patients in the area with neurological care.

After earning a bachelor's degree in neurobiology at Harvard University, Terrelonge earned a master of public health degree at Columbia University's Mailman School of Public Health. He earned his medical degree at Stanford University School of Medicine and completed a residency in neurology at UCSF, serving as chief resident. He also completed a fellowship in neuromuscular medicine at UCSF. During his training at UCSF, he received the Teaching Excellence Award for Cherished Housestaff and was inducted into the Alpha Omega Alpha Honor Medical Society. He is a John A. Watson Faculty Scholar at UCSF.

Education & training

Board certification

  • Neuromuscular Medicine, American Board of Psychiatry and Neurology
  • Neurology, American Board of Psychiatry and Neurology

Fellowship

  • Neuromuscular Medicine, UCSF School of Medicine -GME

Residency

  • Neurology, UCSF School of Medicine -GME

Internship

  • Internal Medicine, UCSF School of Medicine -GME

Degree

  • MD, Stanford University

Academic title

  • Clinical Professor

Locations

    My research

    Reviews

    Average rating

    5
    5 out of 5 Stars
    148 ratings
    About provider reviews

    Showing 1-6 of 41 reviews

    Sort by
    • 5 out of 5 Stars
      August 26, 2026

      Dr. Terrelonge was fantastic - he was everything I was hoping he would be to assist in my challenging diagnosis and eventual care. Totally pleased with him.

    • 5 out of 5 Stars
      August 24, 2026

      Excellent supplier, thank you.

    • 5 out of 5 Stars
      August 24, 2026

      Absolute professional and knowledgeable of his craft it's been a long time since I've had a provider that new what they are talking about about the patient's anatomy and to be very knowledgeable and friendly about it

    • 5 out of 5 Stars
      August 13, 2026

      Both doctors Terrelong and Brambila were excellent.

    • 4.9 out of 5 Stars
      August 9, 2026

      A remarkable team of specialists who really know their stuff.

    • 5 out of 5 Stars
      August 7, 2026

      I have had a long term very favorable relationship with Dr. Terrelonge

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

    For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.

    The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.